Skip to main content

Versant Ventures IV, LLC's Form 4 filing

Oyster Point Pharma, Inc. (OYST) · filed Oct 20, 2021

Accession no.
0000899243-21-040777
Filed
Oct 20, 2021, 4:38 PM ET
Trade date
Oct 18, 2021
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $8.16M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Versant Ventures IV, LLCCIK 000145658910% Owner
Versant Venture Capital IV, L.P.CIK 000145659010% Owner
Versant Side Fund IV, L.P.CIK 000145659110% Owner
Versant Venture Capital VI, L.P.CIK 000168788010% Owner
Versant Vantage I, L.P.CIK 000176525310% Owner
Versant Vantage I GP, L.P.CIK 000177765110% Owner
Versant Ventures VI GP-GP, LLCCIK 000177765210% Owner
Versant Vantage I GP-GP, LLCCIK 000177765310% Owner
Versant Ventures VI GP, L.P.CIK 000177765410% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 18, 2021Common StockSSaleDisposed−303,614$14.63−$4,442,692.581,057,976Indirect
Oct 18, 2021Common StockSSaleDisposed−1,912$14.63−$27,977.726,518Indirect
Oct 18, 2021Common StockSSaleDisposed−242,943$15.09−$3,666,957.35815,033Indirect
Oct 18, 2021Common StockSSaleDisposed−1,531$15.09−$23,108.764,987Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)